Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice

• Published in: International immunopharmacology Vol. 9; no. 12; pp. 1444 - 1451
• Main Authors: Nishitani, Yosuke, Tanoue, Takeshi, Yamada, Katsushige, Ishida, Tsukasa, Yoshida, Masaru, Azuma, Takeshi, Mizuno, Masashi
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier B.V 01.11.2009; Elsevier
• Subjects: Animal models; Animals; Anti-inflammatory; Biological and medical sciences; Caco-2 Cells; Colitis; Colitis - chemically induced; Colitis - immunology; Colitis - microbiology; Colitis - physiopathology; Colitis - therapy; Colon; Colon - immunology; Colon - metabolism; Colon - microbiology; Colon - pathology; Cytokines - genetics; Cytokines - immunology; Cytokines - metabolism; Dextran sulfate; Dextran Sulfate - administration & dosage; Digestive tract; Drinking water; DSS-induced colitis; Enterocytes - immunology; Enterocytes - metabolism; Enterocytes - microbiology; Enterocytes - pathology; Female; g-Interferon; Gene expression; Gene Expression Regulation; Gut inflammation in vitro model; Humans; Immunomodulation; Inflammation; Inflammatory bowel diseases; Inflammatory Bowel Diseases - immunology; Inflammatory Bowel Diseases - microbiology; Inflammatory Bowel Diseases - therapy; Interleukin 6; Interleukin 8; Intestine; Lactococcus lactis; Lactococcus lactis - immunology; Lactococcus lactis subsp. cremoris FC; Lipopolysaccharides; Lipopolysaccharides - metabolism; Macrophages - immunology; Macrophages - metabolism; Macrophages - microbiology; Macrophages - pathology; Medical sciences; Mice; Mice, Inbred C57BL; NF-B protein; NF-kappa B - immunology; NF-kappa B - metabolism; Nitric Oxide Synthase Type II - genetics; Nitric Oxide Synthase Type II - immunology; Nitric Oxide Synthase Type II - metabolism; Nitric-oxide synthase; Nuclear transport; Pharmacology. Drug treatments; probiotics; Probiotics - administration & dosage; Probiotics - pharmacology; Sodium; Tumor necrosis factor-a; Lactococcus lactis subsp. cremoris FC; DSS-induced colitis; Gut inflammation in vitro model; Anti-inflammatory; Lactococcus lactis; Blood substitute; Sodium sulfate; Bacteria; Micrococcales; Intestinal disease; Digestive system; Rodentia; Antiinflammatory agent; Gut; Inflammation; In vitro; Dextran; Streptococcaceae; Symptomatology; Vertebrata; Mammalia; Mouse; Animal; Digestive diseases; Glycosaminoglycan; Models; Colitis
• ISSN: 1567-5769; 1878-1705
• DOI: 10.1016/j.intimp.2009.08.018

Probiotics have been used to treat human gastrointestinal inflammations including inflammatory bowel disease (IBD). However, the exact mechanisms by which probiotics act to protect against intestinal inflammation have yet to be fully elucidated. The aim of this study was to evaluate anti-inflammatory effects of Lactococcus lactis subsp. cremoris FC using in vivo and in vitro inflammation models. Colitis was induced in C57BL/6 mice by administration of 3% dextran sulfate sodium to drinking water. In the cellular level assessment, a gut inflammation model with the co-culture system consisting Caco-2 cells and RAW264.7 cells stimulated by LPS was used. Administration of L. lactis subsp. cremoris FC significantly ameliorated shortening of colon length and histological score of the colon in DSS-induce colitis mice. In addition, the treatment of L. lactis subsp. cremoris FC improved the aberrant mRNA expression in inflamed tissue near to control level through notable suppression of TNF-α ( P < 0.05), IFN-γ ( P < 0.05), IL-6, iNOS, and MIP-2 mRNA expression. In addition, in a gut inflammation model, treatment with L. lactis subsp. cremoris FC resulted in significant down-regulation of IL-8 mRNA expression in Caco-2 cells and inhibition of NF-κB nuclear translocation in RAW264.7 cells. Our findings indicate that administration of L. lactis subsp. cremoris FC improves negative effects of DSS-induced colitis in mice through the inhibition of inflammatory cell infiltration.